Brief: Theratechnologies Announces Preliminary Tolerability And Efficacy Data From Phase 1B, Dose-Ranging Trial Of Sudocetaxel Zendusortide In Patients With Advanced Ovarian Cancer
09/12/2024 13:47
Dec 9 (Reuters) - Theratechnologies TH.TO :
* THERATECHNOLOGIES ANNOUNCES PRELIMINARY TOLERABILITY AND
EFFICACY DATA FROM PHASE 1B, DOSE-RANGING TRIAL OF SUDOCETAXEL
ZENDUSORTIDE IN PATIENTS WITH ADVANCED OVARIAN CANCER
* THERATECHNOLOGIES INC - NO DOSE-LIMITING TOXICITIES
REPORTED IN
TWO DIFFERENT WEEKLY DOSES IN HEAVILY PRE-TREATED PATIENTS IN
PHASE 1B TRIAL
* THERATECHNOLOGIES INC - IN PHASE 1B, PRELIMINARY EVIDENCE
SHOWS
SIGNIFICANT TUMOR SHRINKAGE
Source text: ID:nGNX7S8sB1
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process